Form D · Biotechnology
Garuda Therapeutics, Inc.
Cambridge, MA · CIK 0001884363
Offering snapshot reported Oct 31, 2024 · SEC filing
- Reported sold
- $47.7M Indefinite offering
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 17, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 31, 2024 | Initial | $47,709,955 | No comparison | 16 | SEC filing |
| Feb 3, 2023 | Initial | $62,124,935 | No comparison | 13 | SEC filing |
| Sep 24, 2021 | Initial | $48,123,334 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-528326
Source: Form D, filed Oct 31, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric Aguiar | Director |
| Adam Craig | Director, Executive |
| Shaan Gandhi | Director |
| Carl Gordon | Director |
| Daniel Janse | Director |
| Raymond Kelleher | Director |
| David Kirske | Executive |
| Steve Liapis | Director |
| Geoff Meyerson | Director |
| Laurence Reid | Director |
| Dhvanit I Shah | Director, Executive |
| Rahul Singhvi | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
215 First Street Suite 340 350
Cambridge, MA, 02142
Cambridge, MA, 02142